This time it is: Youth Sports Equipment

The AsepticSure™ system successfully sterilized both naturally and artificially contaminated sports equipment.

Pads and team sweaters were also tested and very effectively sterilized without damaging the textiles or leather. It is noteworthy that the protocol used in gloves heavily contaminated with numerous real world pathogens needed to be adjusted significantly from the hospital protocol in order to obtain full sterilization, which demonstrates the ability of the AsepticSure™ system to meet the many varied demands in the real world through protocol changes without the need to alter the technology. This new work has lead to the development of a decontamination protocol specifically for this application which yields results consistent with those expected in hospital setting of 6 logs (99.9999%, sterilization standard) of bacterial kill. Thus, we have now demonstrated that the AsepticSure™ system is capable of cost effective hospital sterilization, locker room and sports equipment sterilization and in due course, we expect to assume a meaningful role in the bio-terrorism counter measures arena as well.

This application addresses the issue of CA-MRSA, which is the acronym used to describe cases of drug-resistant Staph caught in the community, not in hospitals. Strains caught in hospitals are generally different from those caught outside hospitals.

With colonization, a person carries the microbe _ for instance, on the skin, in the mouth or in the digestive system _ without developing disease. They can, however, pass it to another person, who may become infected.

CA-MRSA has increasingly emerged as a significant infection among people living in the community.  This represents a worldwide pattern, occurring in the U.S., throughout Europe and Australia.

Community-associated MRSA, which has sporadically broken out among professional and amateur sports teams such as the skin infections that bedevilled the USC Trojans and the Cleveland Browns.

When a person is infected with a bacterium or virus, the organisms multiply and can cause injury to a specific tissue or illness throughout the body.

CA-MRSA usually causes severe skin and soft-tissue infections _ but may also cause a fatal lung infection known as necrotizing pneumonia.

In the past five years, there has been a dramatic increase in MRSA occurring in children and younger adults who have no hospital contact or exposure.

While the United States has no national tracking system, however,  in Canada where a national tracking system does exist, in the last two years, almost 40 per cent of all MRSA cases are believed to have arisen in the community, with those at highest risk including younger people, the homeless and imprisoned, and intravenous-drug users.

Over a 13-year period, there was also a three-fold jump in the number of MRSA infections associated with more virulent strains from the community, say researchers from the Canadian Nosocomial Surveillance Program, who conducted the study based on data from 48 sentinel hospitals across the country.

This represents a huge market for Medizone International, Inc.

A Recent Study was the first in Canada to be able to link clinical and epidemiologic data _ for example, the types of patients who are most at risk _ with well-characterized laboratory isolates (bacterial strains), where a specific patient was matched to a specific isolate.

To conduct the study, published in the April issue of the journal Infection Control and Hospital Epidemiology, researchers analyzed hospital data and identified 37,169 patients with either MRSA infection or colonization. The research also included lab tests to isolate and type the various MRSA strains affecting patients.

They found the overall incidence of MRSA increased to more than 11 per 10,000 patient days in 2007 from 0.65 per 10,000 patient days in 1995. Infections associated with MRSA strains from the community also rose significantly, to 23 per cent in 2007 from six per cent in 1995.

Staphylococcus aureus bacteria are commonly found on the skin and can cause a range of problems, from a minor infection in a cut to life-threatening disease. MRSA strains are those that have become immune to the effects of the main antibiotics used to combat the bacteria.

The news in terms of CA-MRSA is picking up steam in addition to the Hospital Acquired Infections.  The AsepticSure™ system has the ability to impact CA-MRSA in addition to Hospital Acquired Infections.

In February 2010 public health researchers reported that six Canadians — one in Ontario, five in Saskatchewan — were infected with methicillin-resistant staphylococcus aureus, or MRSA, drug-resistant staph. That may not sound unusual, but there was something odd about their illnesses: They were caused by a strain that during the last few years has spread through livestock and farm workers in Europe and North America. But the Canadians made sick by the bacterium had no contact with animals or farming; one of them, an elderly woman, had been housebound for several years.

In March 2010, epidemiologists at Johns Hopkins Hospital revealed that 61 per cent of the children in their pediatric intensive care unit — kids enduring advanced cancers, organ transplants and tricky infusions of stem cells — were carrying MRSA, but not the usual hospital strains. Instead, the kids had a strain that predominates outside health care and is more transmissible, more virulent and harder to detect than the hospital variety. While they were counting the cases, one child developed a serious bloodstream infection from the community bug, something that would never have happened just a few years ago.

The AsepticSure™ system is an answer to a serious need both nationally and internationally and within the hospital and in the community.  This means tremendous, tremendous shareholder value.

Contact: Medizone International, Inc. (OTCBB: MZEI)
(See Medizone International Video)
http://www.medizoneint.com

Telephone: 415-868-0300
Fax: 415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

This release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.